Clinical Trials
3 trialsNCT02834013 2026-06-03
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT05407441 2026-04-13
Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors
Dana-Farber Cancer Institute
Phase 1/2 Active not recruiting
NCT04416568 2025-12-17
Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers
Dana-Farber Cancer Institute
Phase 2 Active not recruiting